{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T21:16:26Z","timestamp":1788383786117,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2009,3,9]],"date-time":"2009-03-09T00:00:00Z","timestamp":1236556800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1038\/aps.2009.19","type":"journal-article","created":{"date-parts":[[2009,3,9]],"date-time":"2009-03-09T10:01:40Z","timestamp":1236592900000},"page":"451-457","source":"Crossref","is-referenced-by-count":42,"title":["Berbamine exhibits potent antitumor effects on imatinib-resistant CML cells in vitro and in vivo"],"prefix":"10.1038","volume":"30","author":[{"given":"Yan-lin","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-hua","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-ying","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,3,9]]},"reference":[{"key":"BFaps200919_CR1","first-page":"1497","volume":"132","author":"P Nowell","year":"1960","unstructured":"Nowell P, Hungerford D . A minute chromosome in human chronic granulocytic leukemia. Science 1960; 132: 1497.","journal-title":"Science"},{"key":"BFaps200919_CR2","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/0092-8674(84)90438-0","volume":"37","author":"JB Konopka","year":"1984","unstructured":"Konopka JB, Watanabe SM, Witte ON . An alteration of the human c-ABL protein in K562 leukemia-cells unmasks associated tyrosine kinase-activity. Cell 1984; 37: 1035\u201342.","journal-title":"Cell"},{"key":"BFaps200919_CR3","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/S0301-472X(03)00069-9","volume":"31","author":"D Kirchner","year":"2003","unstructured":"Kirchner D, Duyster J, Ottmann O, Schmid RM, Bergmann L, Munzert G . Mechanisms of bcr-Abl-mediated NF-kappa B\/Re1 activation. Exp Hematol 2003; 31: 504\u201311.","journal-title":"Exp Hematol"},{"key":"BFaps200919_CR4","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/sj.leu.2403241","volume":"18","author":"LS Steelman","year":"2004","unstructured":"Steelman LS, Pohnert SC, Shelton JG, Franklin RA, Bertrand FE, McCubrey JA . JAK\/STAT, Raf\/MEK\/ERK, PI3K\/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 2004; 18: 189\u2013218.","journal-title":"Leukemia"},{"key":"BFaps200919_CR5","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. New Engl J Med 2006; 355: 2408\u201317.","journal-title":"New Engl J Med"},{"key":"BFaps200919_CR6","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1126\/science.1062538","volume":"293","author":"ME Gorre","year":"2001","unstructured":"Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876\u201380.","journal-title":"Science"},{"key":"BFaps200919_CR7","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1182\/blood-2003-12-4121","volume":"104","author":"Y Dai","year":"2004","unstructured":"Dai Y, Rahmani M, Pei XY, Dent P, Grant S . Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr\/Abl-dependent and -independent mechanisms. Blood 2004; 104: 509\u201318.","journal-title":"Blood"},{"key":"BFaps200919_CR8","first-page":"6395","volume":"63","author":"N von Bubnoff","year":"2003","unstructured":"von Bubnoff N, Veach DR, Miller WT, Li WQ, Peschel C, Bornmann WG, et al. Inhibition of wild-type and mutant Bcr-Abl by pyrido-pyrimidine-type small molecule kinase inhibitors. Cancer Res 2003; 63: 6395\u2013404.","journal-title":"Cancer Res"},{"key":"BFaps200919_CR9","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1200\/JCO.1986.4.6.994","volume":"4","author":"WN Hait","year":"1986","unstructured":"Hait WN, Lazo JS . Calmodulin \u2014 a potential target for cancer chemotherapeutic-agents. J Clin Oncol 1986; 4: 994\u20131012.","journal-title":"J Clin Oncol"},{"key":"BFaps200919_CR10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.leukres.2005.05.023","volume":"30","author":"RZ Xu","year":"2006","unstructured":"Xu RZ, Dong QH, Yu YZ, Zhao XY, Gan XX, Wu D, et al. Berbamine: A novel inhibitor of bcr\/abl fusion gene with potent anti-leukemia activity. Leukemia Res 2006; 30: 17\u201323.","journal-title":"Leukemia Res"},{"key":"BFaps200919_CR11","first-page":"754","volume":"25","author":"D Wu","year":"2004","unstructured":"Wu D, Lin MF, Cai Z, Zhao XY . Effects of berbamine on Jurkat cells and its mechanisms in vitro and in vivo. Chin J Hematol 2004; 25: 754\u20136.","journal-title":"Chin J Hematol"},{"key":"BFaps200919_CR12","first-page":"209","volume":"35","author":"ZW He","year":"2006","unstructured":"He ZW, Zhao XY, Xu RZ, Wu D . Effects of berbamine on growth of leukemia cell line NB4 and its mechanism. J Zhejiang Univ (Medical Sci) 2006; 35: 209\u201314.","journal-title":"J Zhejiang Univ (Medical Sci)"},{"key":"BFaps200919_CR13","first-page":"261","volume":"24","author":"L Xu","year":"2003","unstructured":"Xu L, Zhao XY, Wu D . Berbamine, a calmodulin antagonist, induces apoptosis in human leukemia K562 cells. Chin J Hematol 2003; 24: 261\u20132.","journal-title":"Chin J Hematol"},{"key":"BFaps200919_CR14","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1182\/blood.V99.9.3472","volume":"99","author":"S Branford","year":"2002","unstructured":"Branford S, Rudzki Z, Walsh S, Grigg A, Arthur C, Taylor K, et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR\/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 2002; 99: 3472\u20135.","journal-title":"Blood"},{"key":"BFaps200919_CR15","doi-asserted-by":"crossref","first-page":"4545","DOI":"10.1182\/blood.V92.12.4545","volume":"92","author":"Q Chen","year":"1998","unstructured":"Chen Q, Takeyama N, Brady G, Watson AJM, Dive C . Blood cells with reduced mitochondrial membrane potential and cytosolic cytochrome c can survive and maintain clonogenicity given appropriate signals to suppress apoptosis. Blood 1998; 92: 4545\u201353.","journal-title":"Blood"},{"key":"BFaps200919_CR16","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1182\/blood.V91.5.1700","volume":"91","author":"GP Amarante-Mendes","year":"1998","unstructured":"Amarante-Mendes GP, Kim CN, Liu L, Huang Y, Perkins CL, Green DR, et al. Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome c and activation of caspase-3. Blood 1998; 91: 1700\u20135.","journal-title":"Blood"},{"key":"BFaps200919_CR17","first-page":"201","volume":"29","author":"BX Li","year":"1995","unstructured":"Li BX, Gao YR, Li WH . Determination of berbamine in rat plasma by reversed phase high performance liquid chromatography. J Harbin Med Univ 1995; 29: 201\u20133.","journal-title":"J Harbin Med Univ"},{"key":"BFaps200919_CR18","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood.V86.5.1903.bloodjournal8651903","volume":"86","author":"AJ Minn","year":"1995","unstructured":"Minn AJ, Rudin CM, Boise LH, Thompson CB . Expression of Bcl-x(L) can confer a multidrug-resistance phenotype. Blood 1995; 86: 1903\u201310.","journal-title":"Blood"},{"key":"BFaps200919_CR19","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1101\/gad.13.15.1899","volume":"13","author":"A Gross","year":"1999","unstructured":"Gross A, McDonnell JM, Korsmeyer SJ . BCL-2 family members and the mitochondria in apoptosis. Genes Dev 1999; 13: 1899\u2013911.","journal-title":"Genes Dev"},{"key":"BFaps200919_CR20","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1146\/annurev.biochem.69.1.217","volume":"69","author":"A Strasser","year":"2000","unstructured":"Strasser A, O'Connor L, Dixit VM . Apoptosis signaling. Annu Rev Biochem 2000; 69: 217\u201345.","journal-title":"Annu Rev Biochem"},{"key":"BFaps200919_CR21","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1126\/science.1059108","volume":"292","author":"MC Wei","year":"2001","unstructured":"Wei MC, Zong WX, Cheng EHY, Lindsten T, Panoutsakopoulou V, Ross AJ, et al. Proapoptotic BAX and BAK: A requisite gateway to mitochondrial dysfunction and death. Science 2001; 292: 727\u201330.","journal-title":"Science"},{"key":"BFaps200919_CR22","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1182\/blood.V81.11.3091.3091","volume":"81","author":"L Campos","year":"1993","unstructured":"Campos L, Rouault JP, Sabido O, Oriol P, Roubi N, Vasselon C, et al. High expression of Bcl-2 protein in acute myeloid-leukemia cells is associated with poor response to chemotherapy. Blood 1993; 81: 3091\u20136.","journal-title":"Blood"},{"key":"BFaps200919_CR23","first-page":"3115","volume":"57","author":"CN Kim","year":"1997","unstructured":"Kim CN, Wang XD, Huang Y, Ibrado AM, Liu L, Fang GF, et al. Overexpression of Bcl-x (L), inhibits Ara-C-induced mitochondrial loss of cytochrome c and other perturbations that activate the molecular cascade of apoptosis. Cancer Res 1997; 57: 3115\u201320.","journal-title":"Cancer Res"},{"key":"BFaps200919_CR24","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1080\/10245330701384179","volume":"12","author":"Y Baran","year":"2007","unstructured":"Baran Y, Ural AU, Gunduz U . Mechanisms of cellular resistance to imatinib in human chronic myeloid leukemia cells. Hematology 2007; 12: 497\u2013503.","journal-title":"Hematology"},{"key":"BFaps200919_CR25","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1038\/sj.leu.2403207","volume":"18","author":"M Mancini","year":"2004","unstructured":"Mancini M, Brusa G, Benvenuti M, Mazzacurati L, Campanini F, Barbieri E, et al. The (BCR)-B-p210-ABL tyrosine kinase of chronic myeloid leukemia causes resistance to radio-induced apoptotic death by inhibiting the proapoptotic BAX gene. Leukemia 2004; 18: 370\u20132.","journal-title":"Leukemia"},{"key":"BFaps200919_CR26","first-page":"4743","volume":"56","author":"AM Ibrado","year":"1996","unstructured":"Ibrado AM, Huang Y, Fang GF, Liu L, Bhalla K . Overexpression of Bcl-2 or Bcl-x(L) inhibits Ara-C-induced CPP32\/Yama protease activity and apoptosis of human acute myelogenous leukemia HL-60 cells. Cancer Res 1996; 56: 4743\u20138.","journal-title":"Cancer Res"},{"key":"BFaps200919_CR27","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/sj.leu.2403257","volume":"18","author":"T Illmer","year":"2004","unstructured":"Illmer T, Schaich M, Platzbecker U, Freiberg-Richter J, Oelschlagel U, von Bonin M, et al. P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia 2004; 18: 401\u20138.","journal-title":"Leukemia"},{"key":"BFaps200919_CR28","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.exphem.2005.03.014","volume":"33","author":"H Rumpold","year":"2005","unstructured":"Rumpold H, Wolf AM, Gruenewald K, Gastl G, Gunsilius E, Wolf D . RNAi-mediated knockdown of P-glycoprotein using a transposon-based vector system durably restores imatinib sensitivity in imatinib-resistant CML cell lines. Exp Hematol 2005; 33: 767\u201375.","journal-title":"Exp Hematol"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/aps200919.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/aps200919","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/aps200919.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:21:45Z","timestamp":1684412505000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/aps200919"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3,9]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["BFaps200919"],"URL":"https:\/\/doi.org\/10.1038\/aps.2009.19","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,3,9]]}}}